Interview with Anil Raghavan, Country Head – India, Quintiles India
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Address: 301 A-Leela Business Park,M.V. Road, Andheri
Mumbai-59,India
Tel: +91 22 5677 4242
Web: http://www.quintiles.com/
Quintiles Transnational is a pharmaceutical services company offering clinical, commercial, consulting and capital services. The Quintiles network consists of more than 20,000 employees in 60 countries.
Quintiles manages clinical trials on behalf of pharmaceutical customers, and provides the following services:
Management of clinical trials, data, projects and providing laboratory services
Providing customers with sales force, product and brand solutions.
Providing data-driven recommendations to help customers achieve success.
Creating strategic partnerships through financing and operational solutions.
Quintiles India is located amidst a rapidly growing local pharmaceutical market. With five offices spread across the country, we help clients take advantage of a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and tertiary care and teaching hospitals available for trials.
Other advantages: Quintiles India has solid relationships with leading medical centers and experienced English-speaking investigators. All studies are conducted to FDA and ICH GCP standards. Urban India’s literate population provides fast, efficient access to broad population groups with common and special disease profiles, allowing for rapid patient recruitment and faster study start-ups.
Quintiles helped develop or commercialize all of 2009’s top 50 best selling drugs or compounds and nearly 90% of all breakthrough products released on the market between 1996 and 2008.
Key Services in India:
Access to patients
Biostatistics
Central laboratory services
Clinical monitoring and site management
Data management offering a functional service provider (FSP) business model
Drug safety/pharmacovigilance
ECG monitoring services
Project management
Regulatory services
Phase I/IIa
Access through Our India Team to Quintiles Worldwide:
Consulting services
Partnering
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
PAREXEL has had a long-term commitment to India. Could you give us a brief overview of your activities in the country? PAREXEL offers clinical development services throughout India. In 2004,…
TCS Life Sciences and Healthcare vertical was created within the Tata Group 10 years ago. Can you explain to the readers, how such a diversified group such as Tata decided…
Cachet Pharmaceuticals was founded in 1978, what have been your main achievements? We started as a manufacturing company. In the early 1990s we started our own marketing and since then…
With almost EUR 9bn turnover and more than 22,000 people worldwide, Royal DSM has truly grown into an MNC. Within the global market, there is no doubt that India has…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical markets. How have you observed this trend throughout your career? Based on India’s macro-economic growth of around…
India is clearly a new location for Cockram, and what brought you here was your loyal customer Pfizer. After 3 years of project work, a permanent business has now also…
Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in…
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
See our Cookie Privacy Policy Here
